Molbio Diagnostics IPO opened for subscription today, August 10, 2026, attracting attention in the grey market. The point-of-care molecular diagnostics company is commanding a 15% grey market premium (GMP), signalling expectations of a potentially strong listing.
Market analysts have recommended subscribing to the issue, noting that Molbio Diagnostics’ valuations are broadly in line with industry benchmarks. The company is also being offered at a discount to the average P/E multiple of 64.9x for its listed peers, according to analysts.
